IP Library Granted Patent US 12,466,855
Granted Patent B2
US 12,466,855 · App. 18/621,985 · Granted Nov 11, 2025

Labeled oxytocin and method of manufacture and use

Inventors: Steen Jakobsen (Risskov, DK); Michael Winterdahl (Risskov, DK); Erik Nguyen Nielsen (Aarhus V, DK); David C. Yeomans (Sunnyvale, CA); Dean Carson (Palo Alto, CA)
Assignees: TONIX PHARMA LIMITED; AARHUS UNIVERSITY
C07K7/16A61K51/084G01N33/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,855
App. No.
18/621,985
Granted
Nov 11, 2025
Kind
B2
Abstract

Disclosed are 13 N-oxytocin molecules, methods of manufacture of 13 N-oxytocin molecules and methods of use of 13 N-oxytocin molecules in the determination of the distribution and kinetics of 13 N-oxytocin molecules after craniofacial or other application methods.

Claims (23)

1 . A method of manufacturing a compound of Formula IV, wherein the compound is a 13 N-labeled oxytocin peptide comprising the amino acid sequence of SEQ ID NO: 1, the method comprising:

a) converting a compound of Formula (I):

into a compound of Formula (II):

using a R-LG reagent, wherein LG is a leaving group selected from a group comprising CN, OH, O-Acyl, OAt, OBt, Cl, 1-imidazolyl; and

wherein R is P(═O)(OR 1 )(OR 2 );

wherein R 1 and R 2 are independently C 1 -C 6 alkyl or C 6 -C 14 aryl, wherein the C 1 -C 6 alkyl and C 6 -C 14 aryl are independently optionally substituted by halogen, cyano, or C 1 -C 6 alkyl; and

wherein PG1 is an amine protecting group;

b) reacting a compound of Formula (II) with gaseous 13 NH 3 to provide a compound of Formula (III):

c) deprotecting a compound of Formula (III) to provide the compound of Formula IV:

 and

d) purifying the compound of Formula IV.

2 . The method of claim 1 , wherein converting a compound of Formula (I) to a compound of Formula (II) is carried out using the R-LG reagent in the presence of dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), and pentamethylpiperidine (PMP), wherein R-LG is diethyl cyanophosphonate (DECP).

3 . The method of claim 2 , wherein the amount of DECP is between about 0.7 and about 1.1 equivalents.

4 . The method of claim 2 , wherein the ratio of DMSO to THF is between about 1:7 and about 1:11.

5 . The method of claim 1 , wherein the deprotecting comprises reacting a compound of Formula (III) with HCl in dioxane.

6 . The method of claim 1 , wherein the purifying comprises purification by solid-phase extraction (SPE).

7 . The method of claim 6 , wherein purification by SPE comprises:

a) applying the compound of Formula IV to a first hydrophobic SPE column, such that the compound of Formula IV is retained on the first hydrophobic SPE column;

b) applying a solution comprising an aqueous ion-pairing reagent to the first hydrophobic SPE column, such that the compound of Formula IV is eluted in a first eluate;

c) applying the first eluate to a second hydrophobic SPE column, such that the compound of Formula IV of the first eluate is retained on the second hydrophobic SPE column; and

d) eluting the compound of Formula IV in a second eluate.

8 . The method of claim 7 , wherein the first and/or second hydrophobic SPE columns comprise a silica-based bonded phase with strong hydrophobicity.

9 . The method of claim 7 , wherein the solution comprising an aqueous ion-pairing reagent comprises between about 15% and about 25% acetonitrile.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2024
From: TONIX PHARMACEUTICALS HOLDING CORP.
To: TONIX PHARMA LIMITED
Reel/Frame 068094/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2024
From: YEOMANS, DAVID C.; CARSON, DEAN
To: TRIGEMINA, INC.
Reel/Frame 067745/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2024
From: JAKOBSEN, STEEN; WINTERDAHL, MICHAEL; NIELSEN, ERIK HOLM
To: AARHUS UNIVERSITY
Reel/Frame 067745/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2024
From: NIELSEN, ERIK NGUYEN
To: AARHUS UNIVERSITY
Reel/Frame 067745/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2024
From: TRIGEMINA, INC.
To: TONIX PHARMACEUTICALS HOLDING CORP.
Reel/Frame 067745/0769 →
Continuity (3)
Division 16976912
Provisional Application 62637187 · Mar 1, 2018
Related Publication 20240301004A1 · Sep 12, 2024
References Cited (40)
US 1936364A · Pasternack et al. · 1933 [cited by applicant]
US 2260004A · Devenport et al. · 1941 [cited by applicant]
US 2938891A · Velluz et al. · 1960 [cited by applicant]
US 3076797A · Velluz et al. · 1963 [cited by applicant]
US 5988449A · Fuchs et al. · 1999 [cited by applicant]
US 7784460B2 · Djupesland et al. · 2010 [cited by applicant]
US 7854227B2 · Djupesland et al. · 2010 [cited by applicant]
US 9629894B2 · Yeomans et al. · 2017 [cited by applicant]
US 11970554B2 · Jakobsen · 2024 [cited by examiner]
US 20100311655A1 · Leonard et al. · 2010 [cited by applicant]
US 20160193282A1 · Yeomans · 2016 [cited by applicant]
US 20210002331A1 · Jakobsen · 2021 [cited by applicant]
JP 2004161664A · 2004 [cited by applicant]
JP 201085108A · 2010 [cited by applicant]
JP 2016114573A · 2016 [cited by applicant]
WO WO2004062563 · 2004 [cited by applicant]
WO WO2005084715 · 2005 [cited by applicant]
WO WO2006036071 · 2006 [cited by applicant]
WO WO2010116209 · 2010 [cited by applicant]
WO WO2011106732 · 2011 [cited by applicant]
WO WO2012042371 · 2012 [cited by applicant]
WO WO2017096036 · 2017 [cited by applicant]
Atke et al., “Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin,” Acta Endocrinologica, 115(1):155-160 (1987). [cited by applicant]
Blower et al., “Convergent synthesis of 13N-labelled Peptidic structures using aqueous [13N]NH3,” Ejnmmi Radiopharmacy and Chemistry, 2(1):16 (2017). [cited by applicant]
Budesinsky et al., “Synthesis and utilization of 13C and 15N backbone-labeled proline: NMR study of synthesized oxytocin with backbone-labeled C-terminal tripeptide amide,” Amino Acids, 29(2):151-160 (2005). [cited by applicant]
Engstrom et al., “Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation,” European Journal of Pharmacology, 355(2-3):203-210 (1998). [cited by applicant]
Jelinski et al., “C-Terminal 18F-fluoroethylamidation exemplified on [Gly-OH9] oxytocin,” Journal of Labelled Compounds and Radiopharmaceuticals, 45:217-229 (2002). [cited by applicant]
Kheterpal et al., “Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring,” Peptides, 30(7):1276-1281 (2009). [cited by applicant]
Kim et al., “The Prevalence of Anxiety and Mood Problems among Children with Autism and Asperger Syndrome,” Autism, 4(2):117-132 (2000). [cited by applicant]
Kiso et al., “A synthetic method suitable for the rapid preparation of 13N-labeled dermorphin analogue, H-Tyr-D-Met(O)-Phe-Gly-NH2 (SD-62),” Chemical and Pharmaceutical Bulletin, 39(10):2734-2736 (1991). [cited by applicant]
Live et al., “A study of the peptide hormone oxytocin and of prolylleucylglycinamide by nitrogen-15 NMR,” Journal of the American Chemical Society, 101(2):474-479 (1979. [cited by applicant]
Miller et al., “Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography,” Angewandte Chemie International Edition, 47(47):8998-9033 (2008). [cited by applicant]
Saji et al., “Synthesis and biological evaluation of a 13N-labeled opioid peptide,” Nuclear Medicine and Biology, 19(4):455-460 (1992). [cited by applicant]
Smith et al., “Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors,” Bioorganic & Medicinal Chemistry, 20(8):2721-2738 (2012). [cited by applicant]
Staszczuk et al., “Methods of Preparation of Magnesium Organic Compounds from Natural Dolomite,” Physicochem Problems of Mineral Processing, 37:149-158 (2003). [cited by applicant]
Vavere et al., “Molecular Imaging of Cancer with Radiolabeled Peptides and PET,” Anticaner Agents in Medicinal Chemistry, 12(5):462-475 (2012). [cited by applicant]
Veinante et al., “Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study,” Journal of Comparative Neurology, 383(3):305-325 (1997). [cited by applicant]
Wenzel et al., “Development of a Novel Nonpeptidic 18 F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography,” Journal of Medicinal Chemistry, 59(5):1800-1817 (2016). [cited by applicant]
Wisniewki et al., “New, potent, and selective peptidic oxytocin receptor agonists,” Journal of Medicinal Chemistry, 57(12):5306-5317 (2014). [cited by applicant]
Fujii, “Past and future of PET examination”, Japanese Journal of Medical Physics, 35(1):2-9 (2015). [cited by applicant]